JP5663595B2 - ドライアイ症候群の治療のための医薬組成物 - Google Patents

ドライアイ症候群の治療のための医薬組成物 Download PDF

Info

Publication number
JP5663595B2
JP5663595B2 JP2012542577A JP2012542577A JP5663595B2 JP 5663595 B2 JP5663595 B2 JP 5663595B2 JP 2012542577 A JP2012542577 A JP 2012542577A JP 2012542577 A JP2012542577 A JP 2012542577A JP 5663595 B2 JP5663595 B2 JP 5663595B2
Authority
JP
Japan
Prior art keywords
composition
eye
ethanol
treatment
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012542577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513586A (ja
JP2013513586A5 (enExample
Inventor
タイジンガー バスチャン
タイジンガー バスチャン
タイジンガー ゾンニャ
タイジンガー ゾンニャ
グンター バーンハルド
グンター バーンハルド
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5663595(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2013513586A publication Critical patent/JP2013513586A/ja
Publication of JP2013513586A5 publication Critical patent/JP2013513586A5/ja
Application granted granted Critical
Publication of JP5663595B2 publication Critical patent/JP5663595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012542577A 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物 Active JP5663595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
EP09015423.8 2009-12-14
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014203406A Division JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2013513586A JP2013513586A (ja) 2013-04-22
JP2013513586A5 JP2013513586A5 (enExample) 2014-01-09
JP5663595B2 true JP5663595B2 (ja) 2015-02-04

Family

ID=41731659

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012542577A Active JP5663595B2 (ja) 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Country Status (15)

Country Link
US (1) US8614178B2 (enExample)
EP (2) EP2335735A1 (enExample)
JP (5) JP5663595B2 (enExample)
KR (2) KR101722039B1 (enExample)
CN (1) CN102652022B (enExample)
AU (1) AU2010333039B2 (enExample)
BR (3) BR122020020872B1 (enExample)
CA (2) CA2941956C (enExample)
DK (1) DK2512515T3 (enExample)
ES (1) ES2449308T3 (enExample)
IN (1) IN2012DN03128A (enExample)
MX (1) MX2012006720A (enExample)
PL (1) PL2512515T3 (enExample)
PT (1) PT2512515E (enExample)
WO (1) WO2011073134A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921527T3 (es) 2009-06-03 2022-08-29 Forsight Vision5 Inc Administración de fármaco en segmento anterior
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PT2714010T (pt) 2011-05-25 2017-05-05 Novaliq Gmbh Composição farmacêutica tópica à base de alcanos semifluorados
CA2862974C (en) 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CN113679697A (zh) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2883003C (en) * 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
EP2708228B1 (en) 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
CA2899206C (en) 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
CA2905247C (en) 2013-03-13 2021-02-16 Santen Pharmaceutical Co., Ltd. Therapeutic agent for meibomian gland dysfunction
ES2687094T3 (es) 2013-07-23 2018-10-23 Novaliq Gmbh Composiciones estabilizadas de anticuerpos
US20160243291A1 (en) * 2013-10-15 2016-08-25 Forsight Vision5, Inc. Formulations and Methods for Increasing or Reducing Mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
DK3722274T3 (da) * 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CA3036297C (en) * 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
AU2017380769B2 (en) * 2016-12-22 2023-12-21 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
ES2965883T3 (es) * 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
SG11202102818YA (en) 2018-09-22 2021-04-29 Novaliq Gmbh Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
JP7360452B2 (ja) 2018-09-27 2023-10-12 ダーマリック セラピューティクス， インコーポレーテッド 脂質バリアの修復
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
IL322635A (en) * 2023-02-13 2025-10-01 Novaliq Gmbh Ophthalmic preparation for eye surgery in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
DE3851152T2 (de) 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
ES2387619T3 (es) * 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
US20050288196A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer contact lens compositions and methods of use
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
BR112012014190A2 (pt) 2016-05-31
EP2512515B1 (en) 2013-12-25
JP2013513586A (ja) 2013-04-22
CA2941956C (en) 2018-09-04
JP6397472B2 (ja) 2018-09-26
BR122020020872B1 (pt) 2021-09-08
CA2776860A1 (en) 2011-06-23
JP2019006803A (ja) 2019-01-17
EP2335735A1 (en) 2011-06-22
MX2012006720A (es) 2012-07-30
KR20120115977A (ko) 2012-10-19
ES2449308T3 (es) 2014-03-19
WO2011073134A1 (en) 2011-06-23
CA2941956A1 (en) 2011-06-23
CN102652022A (zh) 2012-08-29
AU2010333039B2 (en) 2014-08-28
KR101652714B1 (ko) 2016-09-01
BR112012014190B8 (pt) 2021-05-25
KR20160105533A (ko) 2016-09-06
US8614178B2 (en) 2013-12-24
JP6731039B2 (ja) 2020-07-29
JP2019070003A (ja) 2019-05-09
BR122017018955B1 (pt) 2022-03-08
US20120244177A1 (en) 2012-09-27
JP2015028064A (ja) 2015-02-12
BR112012014190B1 (pt) 2021-03-02
AU2010333039A1 (en) 2012-07-12
CA2776860C (en) 2016-10-25
PT2512515E (pt) 2014-03-04
EP2512515A1 (en) 2012-10-24
CN102652022B (zh) 2014-12-17
PL2512515T3 (pl) 2014-05-30
JP6096731B2 (ja) 2017-03-15
KR101722039B1 (ko) 2017-03-31
DK2512515T3 (en) 2014-03-10
JP2017078086A (ja) 2017-04-27
IN2012DN03128A (enExample) 2015-09-18
HK1172269A1 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
JP6731039B2 (ja) ドライアイ症候群の治療のための医薬組成物
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
CN102869345B (zh) 用于治疗眼内压增高的药物组合物
JP5836473B2 (ja) 眼科用組成物
HK1172269B (en) Pharmaceutical composition for treatment of dry eye syndrome
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131113

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131113

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141208

R150 Certificate of patent or registration of utility model

Ref document number: 5663595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250